Michael Artinger, PhD

Michael Artinger, PhD
Michael Artinger, PhD, Executive Vice President and Managing Director VIC Colorado Branch, has spent his career transforming innovation into commercial opportunity. He has worked closely with universities and inventors across the nation to recognize the potential of their discoveries and has deep domain expertise across multiple verticals, including therapeutics, vaccines, medical devices, diagnostics and information technology/software. Dr. Artinger earned his Doctorate degree in Biology focusing on Developmental and Cell Biology, as well as his Baccalaureate degree in Applied Ecology from the University of California at Irvine.
Find me on:

Recent Posts

Challenges and Solutions for University Technology Commercialization (Part 2)

In Part 1 of this series, I touched on some of the unique considerations for advancing early-stage innovation beyond the academic setting. For this article, I’d like to dig deeper into the topic of university...

Challenges and Solutions for University Technology Commercialization (Part 1)

The honest truth? Deciding which early-stage technologies will be successful is really hard. This is even more the case when you add the challenges faced in a university setting. Although I’m currently on the investment...

From the Corner Office: Neurexis Therapeutics

Let me start by saying that the last two years have been a case study on focusing on priorities and filtering out noise. I’m fortunate to work in an area where it’s easy to see the long-term value of what we...

The Accelerating Pace of Life Science Innovation in a (Soon-to-Be) Post-Pandemic World

As discussed in my previous article “Portfolio Diversification During Times of Market Volatility,”[1] one of the few positive outcomes of the worldwide pandemic is the increasing recognition of the power of innovation...

Inside The VIC Fellows Program

VIC Technology Venture Development’s (www.victech.com) investment model sources promising life science innovation directly from universities across the nation, allocating funding to form startup companies and advance...

Portfolio Diversification in Times of Market Volatility

Update It is now March 2021, and nine months after writing this piece below, saying that things have evolved would be an understatement. Focusing on the positive progress made to date, we have three approved vaccines in...

The Emerging Remote Workplace: Digital Best Practices for Investor Groups

As the recent pandemic has made all too clear, organizations need to proactively prepare for the realities of a dispersed workforce, which is especially true for investor groups such as venture capital and private...

White Paper: New Paradigms of Life Science Investing

For decades, only venture capital (VC) firms, and very rarely, angels were able to invest in start-up companies developing life science—therapeutics, medical devices, diagnostics, and related—innovation.  Anyone doing...

White Paper: Accessing Innovation Directly From The Source - The Growing Trend Of Venture Capital Company Formation

Historically, innovative technologies discovered at universities, institutes and national labs have had two primary paths towards commercialization: (1) licensing to a large, pre-existing company; or, (2) licensing to...


VIC Tech Continues to Grow Its Medical Advisory Board
Zero Federal Capital Gains Taxes on High-Return Investments
White Paper
Portfolio Diversification in Times of Market Volatility
Inside CTTC at Vanderbilt University with Assistant Director, Physical Sciences Ashok Choudhury
Seven Reasons Venture Capital-Stage Companies Should Become Part of Your Investment Portfolio
White Paper
Investing in Medical Devices & Diagnostics – Industry Trends and Investor Activity
Cellia Science Formed to Develop and Commercialization Point-of-Care Hematology Analyzers
VIC Fellows Spotlight: Alexandra Antonioli, MD, PhD
From The Corner Office
SFC Fluidics Nears FDA Submission